

Hydrix (ASX:HYD) shares soar after first U.S. AngelMed Guardian implant

Health Care

ASX:HYD MCAP \$33.98M

Ashleigh Melanko 01 October 2020



- Hydrix (HYD) was up more than 61 per cent on the market this morning after it completed the first implant of AngelMed Guardian in a U.S. patient
- The implant was performed by Director of Electrophysiology at the Orange County Heart Institute and Research Center in California
- The AngelMed Guardian uses machine learning algorithms and artificial intelligence to continuously monitor the patient's heart signal
- This then warns medical professionals of any coronary syndromes, such as silent heart attacks
- Hydrix shares are currently still up a healthy 51.9 per cent and shares are trading for 41 cents each

Hydrix (HYD) shares have jumped up 61 per cent on the market this morning after the company announced it had completed the first implant of AngelMed Guardian in a U.S. patient.

The implant was performed by Director of Electrophysiology at the Orange County Heart Institute and Research Center in California, Kelly Tucker, M.D.

While the patient is a former ALERTS Study patient, and the implant was part of the wider ALERTS-Continued Access Study.

The aim of this continued study is to provide former ALERTS patients access to Hydrix's next generation device.

"The AngelMed Guardian represents a real game changer in the management of coronary artery disease," Kelly said.

"This is the first ever surveillance tool for patients with a prior coronary event and has the potential to save countless lives and bring peace of mind to thousands of families," he added.

The AngelMed Guardian uses machine learning algorithms and artificial intelligence to continuously monitor the patient's heart signal and warn of any coronary syndromes, such as silent heart attacks.

"This is a significant step forward in the progress of the AngelMed Guardians's commercialisation. We congratulate the team involved and look forward to ongoing positive news," Hydrix General Manager Paul Kelly said.

Following the announcement of the successful implant, shares in the company soared. Hydrix is still up a healthy 51.9 per cent and shares are trading for 41 cents each at 11:22 am AEST.

<https://themarketherald.com.au/hydrix-asxhyd-shares-soar-after-first-u-s-angelmed-guardian-implant-2020-10-01/>